Opportunity in Complexity: Harnessing Molecular Biomarkers and Liquid Biopsies for Personalized Sarcoma Care

IF 2.6 3区医学 Q3 ONCOLOGY

Seminars in Radiation Oncology Pub Date : 2024-03-18 DOI:10.1016/j.semradonc.2023.12.002

Agnes Ewongwo , Caressa Hui , Everett J. Moding

{"title":"Opportunity in Complexity: Harnessing Molecular Biomarkers and Liquid Biopsies for Personalized Sarcoma Care","authors":"Agnes Ewongwo , Caressa Hui , Everett J. Moding","doi":"10.1016/j.semradonc.2023.12.002","DOIUrl":null,"url":null,"abstract":"<div>Due to their rarity and complexity, sarcomas represent a substantial therapeutic challenge. However, the incredible diversity within and across sarcoma subtypes presents an opportunity for personalized care to maximize efficacy and limit toxicity. A deeper understanding of the molecular alterations that drive sarcoma development and treatment response has paved the way for molecular biomarkers to shape sarcoma treatment. Genetic, transcriptomic, and protein biomarkers have become critical tools for diagnosis, prognostication, and treatment selection in patients with sarcomas. In the future, emerging biomarkers like circulating tumor DNA analysis offer the potential to improve early detection, monitoring response to treatment, and identifying mechanisms of resistance to personalize sarcoma treatment. Here, we review the current state of molecular biomarkers for sarcomas and highlight opportunities and challenges for the implementation of new technologies in the future.</div>","PeriodicalId":49542,"journal":{"name":"Seminars in Radiation Oncology","volume":"34 2","pages":"Pages 195-206"},"PeriodicalIF":2.6000,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Radiation Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1053429623000875","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Due to their rarity and complexity, sarcomas represent a substantial therapeutic challenge. However, the incredible diversity within and across sarcoma subtypes presents an opportunity for personalized care to maximize efficacy and limit toxicity. A deeper understanding of the molecular alterations that drive sarcoma development and treatment response has paved the way for molecular biomarkers to shape sarcoma treatment. Genetic, transcriptomic, and protein biomarkers have become critical tools for diagnosis, prognostication, and treatment selection in patients with sarcomas. In the future, emerging biomarkers like circulating tumor DNA analysis offer the potential to improve early detection, monitoring response to treatment, and identifying mechanisms of resistance to personalize sarcoma treatment. Here, we review the current state of molecular biomarkers for sarcomas and highlight opportunities and challenges for the implementation of new technologies in the future.

查看原文本刊更多论文

复杂中的机遇：利用分子生物标记物和液体活检实现个性化肉瘤治疗

由于其罕见性和复杂性，肉瘤是一项巨大的治疗挑战。然而，肉瘤亚型内部和亚型之间令人难以置信的多样性为个性化治疗提供了机会，以最大限度地提高疗效并限制毒性。人们对推动肉瘤发展和治疗反应的分子改变有了更深入的了解，这为分子生物标记物治疗肉瘤铺平了道路。基因、转录组和蛋白质生物标志物已成为肉瘤患者诊断、预后和治疗选择的重要工具。未来，循环肿瘤 DNA 分析等新兴生物标记物有可能改善早期检测、监测治疗反应和识别抗药性机制，从而实现肉瘤治疗的个性化。在此，我们回顾了肉瘤分子生物标记物的现状，并强调了未来实施新技术的机遇和挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Seminars in Radiation Oncology 医学-核医学

CiteScore

5.80

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Each issue of Seminars in Radiation Oncology is compiled by a guest editor to address a specific topic in the specialty, presenting definitive information on areas of rapid change and development. A significant number of articles report new scientific information. Topics covered include tumor biology, diagnosis, medical and surgical management of the patient, and new technologies.